Literature DB >> 21420985

Insulin signaling and addiction.

Lynette C Daws1, Malcolm J Avison, Sabrina D Robertson, Kevin D Niswender, Aurelio Galli, Christine Saunders.   

Abstract

Across species, the brain evolved to respond to natural rewards such as food and sex. These physiological responses are important for survival, reproduction and evolutionary processes. It is no surprise, therefore, that many of the neural circuits and signaling pathways supporting reward processes are conserved from Caenorhabditis elegans to Drosophilae, to rats, monkeys and humans. The central role of dopamine (DA) in encoding reward and in attaching salience to external environmental cues is well recognized. Less widely recognized is the role of reporters of the "internal environment", particularly insulin, in the modulation of reward. Insulin has traditionally been considered an important signaling molecule in regulating energy homeostasis and feeding behavior rather than a major component of neural reward circuits. However, research over recent decades has revealed that DA and insulin systems do not operate in isolation from each other, but instead, work together to orchestrate both the motivation to engage in consummatory behavior and to calibrate the associated level of reward. Insulin signaling has been found to regulate DA neurotransmission and to affect the ability of drugs that target the DA system to exert their neurochemical and behavioral effects. Given that many abused drugs target the DA system, the elucidation of how dopaminergic, as well as other brain reward systems, are regulated by insulin will create opportunities to develop therapies for drug and potentially food addiction. Moreover, a more complete understanding of the relationship between DA neurotransmission and insulin may help to uncover etiological bases for "food addiction" and the growing epidemic of obesity. This review focuses on the role of insulin signaling in regulating DA homeostasis and DA signaling, and the potential impact of impaired insulin signaling in obesity and psychostimulant abuse.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420985      PMCID: PMC3518862          DOI: 10.1016/j.neuropharm.2011.02.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  73 in total

1.  Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat.

Authors:  D P Figlewicz; S B Evans; J Murphy; M Hoen; D G Baskin
Journal:  Brain Res       Date:  2003-02-21       Impact factor: 3.252

Review 2.  How does calorie restriction work?

Authors:  Jana Koubova; Leonard Guarente
Journal:  Genes Dev       Date:  2003-02-01       Impact factor: 11.361

3.  Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats.

Authors:  Ruggero Galici; Aurelio Galli; David J Jones; Teresa A Sanchez; Christine Saunders; Alan Frazer; Georgianna G Gould; Richard Z Lin; Charles P France
Journal:  Neuroendocrinology       Date:  2003-02       Impact factor: 4.914

4.  Impulsivity and rapid discounting of delayed hypothetical rewards in cocaine-dependent individuals.

Authors:  Scott F Coffey; Gregory D Gudleski; Michael E Saladin; Kathleen T Brady
Journal:  Exp Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.157

5.  Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin.

Authors:  Kevin D Niswender; Byron Gallis; James E Blevins; Marshall A Corson; Michael W Schwartz; Denis G Baskin
Journal:  J Histochem Cytochem       Date:  2003-03       Impact factor: 2.479

6.  Insulin induces a novel form of postsynaptic mossy fiber long-term depression in the hippocampus.

Authors:  Chiung-Chun Huang; Jia-Lin You; Cheng-Che Lee; Kuei-Sen Hsu
Journal:  Mol Cell Neurosci       Date:  2003-11       Impact factor: 4.314

Review 7.  The source of cerebral insulin.

Authors:  William A Banks
Journal:  Eur J Pharmacol       Date:  2004-04-19       Impact factor: 4.432

8.  Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.

Authors:  Effat S Emamian; Diana Hall; Morris J Birnbaum; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Genet       Date:  2004-01-25       Impact factor: 38.330

Review 9.  Structure, regulation and function of PKB/AKT--a major therapeutic target.

Authors:  Masahito Hanada; Jianhua Feng; Brian A Hemmings
Journal:  Biochim Biophys Acta       Date:  2004-03-11

10.  PI 3-kinase regulation of dopamine uptake.

Authors:  Lucia Carvelli; José A Morón; Kristopher M Kahlig; Jasmine V Ferrer; Namita Sen; James D Lechleiter; L M Fredrik Leeb-Lundberg; Gerald Merrill; Eileen M Lafer; Lisa M Ballou; Toni S Shippenberg; Jonathan A Javitch; Richard Z Lin; Aurelio Galli
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

View more
  38 in total

1.  Trans and interesterified fat and palm oil during the pregnancy and lactation period inhibit the central anorexigenic action of insulin in adult male rat offspring.

Authors:  Kenia Pereira Bispo; Letícia de Oliveira Rodrigues; Érica da Silva Soares de Souza; Daniela Mucci; Maria das Graças Tavares do Carmo; Kelse Tibau de Albuquerque; Fatima Lucia de Carvalho Sardinha
Journal:  J Physiol Sci       Date:  2014-11-15       Impact factor: 2.781

2.  Food restriction increases acquisition, persistence and drug prime-induced expression of a cocaine-conditioned place preference in rats.

Authors:  Danielle Zheng; Soledad Cabeza de Vaca; Kenneth D Carr
Journal:  Pharmacol Biochem Behav       Date:  2011-10-29       Impact factor: 3.533

3.  Insulin signaling genes modulate nicotine-induced behavioral responses in Caenorhabditis elegans.

Authors:  Seth A Wescott; Elizabeth A Ronan; X Z Shawn Xu
Journal:  Behav Pharmacol       Date:  2016-02       Impact factor: 2.293

4.  mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Authors:  Olga I Dadalko; Michael Siuta; Amanda Poe; Kevin Erreger; Heinrich J G Matthies; Kevin Niswender; Aurelio Galli
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

5.  Dietary supplementation with fish oil prevents high fat diet-induced enhancement of sensitivity to the locomotor stimulating effects of cocaine in adolescent female rats.

Authors:  Katherine M Serafine; Caitlin Labay; Charles P France
Journal:  Drug Alcohol Depend       Date:  2016-05-24       Impact factor: 4.492

6.  Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain.

Authors:  Kymry T Jones; Catherine Woods; Juan Zhen; Tamara Antonio; Kenneth D Carr; Maarten E A Reith
Journal:  J Neurochem       Date:  2017-01-31       Impact factor: 5.372

7.  Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function.

Authors:  Jeremy M Veenstra-Vanderweele; Aurelio Galli; Christine Saunders; Michael Siuta; Sabrina D Robertson; Adeola R Davis; Jennifer Sauer; Heinrich J G Matthies; Paul J Gresch; David Airey; Craig W Lindsley; John A Schetz; Kevin D Niswender
Journal:  Neurochem Int       Date:  2013-09-30       Impact factor: 3.921

8.  High-Fat-Diet-Induced Deficits in Dopamine Terminal Function Are Reversed by Restoring Insulin Signaling.

Authors:  Steve C Fordahl; Sara R Jones
Journal:  ACS Chem Neurosci       Date:  2017-01-03       Impact factor: 4.418

9.  Enhanced cocaine-induced locomotor sensitization and intrinsic excitability of NAc medium spiny neurons in adult but not in adolescent rats susceptible to diet-induced obesity.

Authors:  Max F Oginsky; Joel D Maust; John T Corthell; Carrie R Ferrario
Journal:  Psychopharmacology (Berl)       Date:  2015-11-27       Impact factor: 4.530

10.  Effects of time of feeding on psychostimulant reward, conditioned place preference, metabolic hormone levels, and nucleus accumbens biochemical measures in food-restricted rats.

Authors:  Danielle Zheng; Shan Liu; Soledad Cabeza de Vaca; Kenneth D Carr
Journal:  Psychopharmacology (Berl)       Date:  2013-01-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.